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INTRODUCTION 
          The biggest medical breakthroughs of this century are 
transplantation of human organs. The escalating End stage Renal Disease 
population and the lack of suitable donors – this discrepancy is well 
known. The first deceased donor renal transplantation in our hospital was 
performed in the year 1996 with 73 deceased donor transplantations 
performed thereafter. 
          Though deceased donor transplantation was started in the year 
1996, it started gathering momentum only after the year 2008, when a 
doctor couple donated their brain-dead son’s organ, which gained 
widespread public attention. 
          The rate of deceased donors per million in India is far behind the 
world average rate. When compared with other countries like United 
States, Portugal and Spain the renal transplantation rate in India with a 
population of about 1.3 billion is only 3.2 per million population. 
         The major cause of End Stage Renal Disease are Diabetes and 
Hypertension which is on the increase. The age-adjusted incidence of end 
stage renal disease is estimated to be 232 per million population. 
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   The only hope for patients with ESRD is renal transplantation, as the 
dialysis  centres are limited to certain regions especially they are 
concentrated in the urban cities and is also expensive in the long run. The 
importance of this scenario is exemplified by this. 
   The only way to combat the commercial organ transplantation is to 
increase the deceased donor transplantation. It also reduces the burden on 
the live related renal transplantation. 
     Until a decade ago there was a lack of knowledge among the general 
public about deceased organ donation. But the crucial role played by the 
non governmental organization and media in support by the government 
implemented the deceased donor programme in the state of Tamilnadu 
successfully. 
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AIMS 
1. TO ANALYSE THE VARIOUS DONOR AND RECIPIENT 
CHARACTERISTICS. 
2. TO ANALYSE THE POST TRANSPLANT INFECTIONS AND 
POST OPERATIVE COMPLICATIONS 
3. TO ANALYSE THE INFECTION RATES AND ACUTE 
REJECTION RATES WITH THE USE OF INDUCTION 
IMMUNOSUPPRESSION. 
4. TO ANALYSE THE PATIENT SURVIAL RATES. 
5. TO ANALYSE THE GRAFT SURVIVAL RATES. 
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 MATERIALS AND METHODS 
    This was a prospective and a partly retrospective study 
conducted from October 2008 to March 2014. 
INCLUSION CRITERIA 
 All patients who underwent deceased donor renal transplantation 
in our centre were included in the study. 
EXCLUSION CRITERIA 
   All patients who underwent live renal transplantations were 
excluded from the study. 
STATISTICAL METHODS 
•  The various donor and recipient characteristics , cold ischemic 
time (CIT), tacrolimus levels, post transplant infections were 
analysed using multivariable Cox regression model, Pearson chi 
square test, Fisher’s exact test. 
• Kaplan-Meier analysis to evaluate survival rates of patient & graft 
at 1 year & 4 years  
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REVIEW OF LITERATURE  
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               The renal replacement therapy options available for patients 
with  End  Stage  Renal  Disease  are  dialysis  or  transplantation.  Dialysis  
could be either peritoneal or haemodialysis. Despite achieving the targets 
for adequate haemodialysis / Peritoneal Dialysis and better management 
of anaemia with erythropoietin, the quality of life is poor when compared 
to transplantation. Patients on dialysis tend to have progressive, 
peripheral and autonomic neuropathy, bone disease and progressive 
Cardio Vascular Disease.1, 2 
          The cumulative costs of Dialysis either Haemodialysis or 
Peritoneal Dialysis is much more than that of a transplantation over a 
period of five years.3 The life-expectancy in dialysis is far lower than 
patients who had received a transplant. The long term survival rates for 
renal transplant recipients were better who received either an ideal or 
marginal donor. Though there is increased mortality rates associated with 
the surgical procedure and immunosuppressive drugs the survival benefit 
can be recognized within the one year of transplantation.4 
   The extent of the survival benefit varies depending upon the quality of 
the transplanted kidney and the patient profile at the time the patient is 
enrolled on the waiting list. It is very high for both young and diabetic 
patients. A high quality donor kidney has the capacity to about double the 
anticipated life span of a waitlisted dialysis patient.5 
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                  Hence, undoubtedly renal transplantation has the highest 
potential for restoring a healthy, productive life in most patients with End 
stage renal disease. The donor options available are living related, living 
unrelated (emotionally related) and deceased donors. The disparity 
between the escalating End Stage Renal Disease population and 
availability of living donors is well known. The only other option 
available for these populations is Deceased donor renal transplantation.6, 7 
INDIAN SCENARIO 
    As  per  the  Chronic  Kidney  Disease  Registry  of  India,  the  crude  and  
age-  adjusted   incidence  rates   of  End  Stage  Renal  Disease  (ESRD)   is  
estimated to be 151 – 232 per million population per year, respectively in 
our country. The renal transplantation rates are only 3.20 per million 
populations per year. Renal transplantation offers better survival,8 Quality 
of life9 and is cost effective.10 
        The availability of live related donor and costs are major barrier to 
transplantation in India. The renal transplantation rate in India with a 
population of 1.2 billion is only 3.25 per million population which is far 
below when compared to other counties like Spain and United States.11 
The mismatch between the escalating ESRD patients and availability of 
organs for transplantation is significantly reduced by deceased donor 
transplantation. 12, 13 
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             In the year of 2012 due to Road traffic accidents, 3,94,982 people 
have died  and more than three-fourths among them are brain dead.14 
There are several important steps in Deceased donor transplantation 
which involves  brain death declaration, getting consent from the 
relatives, harvesting and storage of organs and taking it to the  hospital 
for transplantation.    More difficulty is encountered in the initial two 
stages. 
SPANISH MODEL 
           Large numbers of brain death donors arise from critical care wards 
and hence therefore they are the place where organ donations have to be 
more concentrated for. Huge numbers are lost only due to not identifying 
them at the correct time. Hence the critical care ward doctor in charge 
should  be  vigilant  regarding  the  same  and  as  a  part  of  end  of  life  care  
promote the idea of organ donation. Spain's legal framework of presumed 
consent is frequently attributed to its success. There was no impact on 
donation rates with the introduction of opting out of deceased donation in 
1979. The donation rates have increased further in Spain with the 
implementation of separate organization for transplant at the national 
level and persons to coordinate the donors.15  
THE NEED FOR A MODEL 
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          Commercialisation of organ transplants increased in various 
regions India increased only due to the mismatch between the supply and 
demand.                  
            Accordingly the government of Tamil Nadu decided to curb the 
commercialisation of renal transplantation by promoting deceased donor 
transplantation.16 
               The transplantation of Human Organs Act was promulgated by 
the Indian government in 1994 and thereafter deceased donor 
transplantation Program was initiated. Then to maintain the demand and 
supply  of  organs  in  a  particular  part  a  protocol  was  needed.  The  supply  
was grossly outnumbered by the demand of deceased donor organs.  
                  When there was an illicit organ transplant scam arose in the 
year 2007, the Tamil Nadu Government made policies to encourage 
deceased donor transplantations.  Workshops were organized between the 
public and private to encourage partnership in which medical personnel, 
NGOs and officials participated in large numbers. 
                   To make DDT program more popular among general public 
many NGOs joined with the Government.  A model of transplantation 
was needed which maintain all the current activities of organ 
transplantation and help to escalate the DDT.17 
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                      DDT is a goal that is easily achievable and is the right way 
of doing things. There are approximately two lakh people. According to 
National Crime Records Bureau (NCRB) there is about 1,35,000 road 
traffic mortalities in 2010.       
               As per the Indian Journal of Neurotrauma in 2008, about 69 % 
have brain death. If most of the families consent to donate then there will 
be 90,000 potential organ donors. Only a small percentage of these 
donors are sufficient to meet the ends for various organ donations. Hence 
all these facts suggest the model with transparent activities there will be 
an end to illicit organ transplantation by meeting the organ requirement of 
the patients.  
              To supplement the Tamil Nadu Human Organs Transplantations 
ACT 1994, the government set guidelines and promulgated orders to lay 
down a set of norms.18 
THE TAMILNADU EXPERIENCE 
            Deceased donor transplantation is very much eligible to be the 
main source of organ transplantation requirements and there are various 
reasons for it. Several lives could be saved and commercialisation of 
transplantation can be   eliminated. There is also decreased need for near 
relatives to donate their organs and they are without any moral 
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compulsion. The wealthy and economically downtrodden will benefit 
from it. If only the relatives of the deceased donors are made aware most 
of they would be willing to do so. The infrastructure and other logistics 
are available for this to happen.19 
         When compared to other countries, India is far behind in the rates of 
human organ transplantation. The four cardinal States that intensely 
practice deceased donor transplantation are, Maharashtra, Andhra 
Pradhesh, Gujarat and Tamil Nadu. 
        There were studies done in deceased donor survival rates in Tamil 
Nadu and Gujarat. The study done in Gujarat with 160 deceased donor 
transplantation, which was a single centre experience showed a mean 
follow up of 2.35± 1.24 years with patient and graft survival rates of 77.5 
% and 89.5 %. The study from Tamil Nadu which was also a single 
centre experience showed patient survival rates of 79. 8 % and 74.8 % at 
1 and 3 years respectively. The same study showed the graft survival 
rates which was censored for death as 92.4 % and 87.9 % at 1 and 3 years 
respectively.20 
     From October 2008 to March 2014, the Tamil Nadu Deceased donor 
transplant programme facilitated the retrieval of  2508 organs from 454 
deceased donors. The average rate of generation of deceased donors in 
the state of Tamil Nadu is seven per month at present. When compared 
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head on with International Standards it far behind, but when compared 
head on with other states in India it is more than ten times more. 
     
THE ROLE OF NON GOVERNMENTAL ORGANIZATIONS 
(NGOs) 
        The Deceased donor transplantation programme was made 
successful in our State because it was the ensuing collaborative effort 
involving the NGOs, private sectors and the State Government.  The team 
work of them starts early with the identification of deceased donor, 
maintenance in the dedicated intensive care unit, counselling given to the 
donor families who have lost their dear ones and timely organ retrieval, 
which is coordinated by the  transplant coordinator and involves the joint 
effort of NGOs and the hospital in which the transplant is done.21 
       NGOs also played a crucial role in the success of this program in the 
state of Tamil Nadu. The cardinal work done by, MOHAN (Multi organ 
Harvest Aid Network) an NGO for the past fifteen years and has 
coordinated organ transplantation very well.  
      The effective implementation and its success have attracted many 
other states and also the defence personnel. Indian defence forces through 
their hospital network implemented successfully this program and more 
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than forty thousand army personnel have pledged their organs in case 
accidental death. 
     The Rajiv Gandhi Government General Hospital alone have played a 
crucial role in the success  of this programme and have counselled several 
families with a conversion rate of 66 %. More than 300 organ and tissues 
were harvested and transplanted from 62 deceased donors in this hospital. 
The important stake holders include media which played a crucial role in 
the total frame work of deceased donor transplantation programme. Their 
motto is ‘deceased donor organ transplantation saves lives; it can 
eliminate illegal organ trade’.22 
THE TAMIL NADU MODEL 
       The deceased donor transplantation program is effectively 
functioning through a framework that promotes organ allocation which is 
fair and transparent manner only to support the recipient. 
        The  structure  of  this  model  is  comprised  of  an  anchor;  he  is  also  
called the Convener in this programme. His role is to maintain the list of 
recipients who are waiting for transplantation and allocate organs, collect 
data on transplantation and maintaining the statistics, to arrange for 
periodic meetings and creating programs on awareness. 
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        His effort is supported by the advisory committee that has been 
formed to establish formats and procedures, to supervise the compliance 
with the same procedure, to adequately ensure the stability of functioning 
of  the  program  and  to  streamline  the  program  by  recommending  a  
coordination body. 
        Certain sub-committees have also been set up by the advisory 
committee to provide inputs for the same and are available for help and 
consultation and aiding in the decision making. There are various sub-
committees for renal, heart, liver and lung transplantation. This 
framework functions as per the orders of the state government and the 
advisory committee guidelines. 
    The Tamil Nadu model involves the allocation of one kidney, liver and 
heart automatically to the same hospital where there is declaration of 
brain death and they are called local organs. The second kidney, the heart 
and liver if not used by the local hospital will become shared organs and 
is given to others hospital on priority basis and guidelines.23 
IMPORTANT GOVERNMENT ORDERS 
1. Declaration of brain death has been made compulsory IN 
Government Medical College Hospitals in Chennai – Orders 
issued. G.O (Ms) No.6 dated: 08.01.2008. 
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2. Procedure for declaration of brain death in Government Medical 
college hospital. 
3. Health  and  Family  Welfare  Department  –  Organ  donation  –  
Responsibilities of transplant centres in hospitals. G.O (Ms) 
No.288 dated: 05.09.2008. 
4. Health and Family Welfare Department – Deceased donor 
transplantation _ Post-mortem examination in medico-legal cases 
– procedures. 
5. Health and Family Welfare Department – Cadaver transplantation 
_ Participation of private hospitals in the state – made 
compulsory. Orders issued.24 
 
THE ROLE OF TRANSPLANT COORDINATOR 
     The transplant coordinator should be available round the clock 
and should in touch with the convener with two other medical officers in 
the hospital. He also makes sure that the hospital creates a waiting list of 
patients who are awaiting transplantation. And it is also frequently 
updated. The full details of the recipient with the emergency contact 
phone numbers should be available in the hospital. 
    He should also be in constant touch with the intensive care 
doctor in case there is any brain death is suspected and make 
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arrangements for certification of brain death and offer grief counselling to 
the relatives. He should also inform the convener immediately once the 
family is willing to donate. He should also give the full details of the 
donor to the convener. 
           All the allocation and prioritisation of the organs is done under the 
norms of the government to maintain the transparency. 
 
 The shared kidney if it is from a government hospital will be given 
in the following priority, 
x Combined government hospital list 
x Combined private hospitals list 
x Government hospital outside the state 
x Private hospitals outside the state 
x Foreign national in/out of state. 
The shared kidney from a private hospital is allocated as follows, 
x Combined government and private hospitals list 
x Government / private hospital outside the state 
x Foreign national in or out of state. 
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ENHANCEMENT OF PUBLIC AWARENESS25 
The Tamil Nadu model not only framed vital rules and regulation 
for the allocation of organs but also played an important role in creating 
awareness about the programme. Public awareness is useful in building 
a conducive environment for governments and the hospitals to work in. 
By ensuring that influential persons in society sign up as organ donors 
we can create awareness. There is also a concept of donor card created 
by this program. Having this card sensitises the relatives to donate 
organs during the right situation. The whole exercise is coordinated by 
the convener. Highest record of transplants was recorded following 
successful implementation of this program and five hospital in the state 
contributed the vast majority. 
The state of Tamil Nadu has the highest deceased donor 
transplantation rate in India only through public-private partnership. The 
current rate in our state is 1.3 million which more than 15 times of the 
national average. 
BRAIN DEATH AND OTHER MEDICO LEGAL 
ISSUES 
The stage at which all functions of the brain-stem have 
permanently and irreversibly ceased is considered as brain death. The 
Human organs transplantation act also makes it legal death, provided the 
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certification is carried out as per norms. The declaration of brain death is 
made mandatory in all the government medical college hospitals in 
Chennai and issued procedures for the same. 
For the certification of brain death, four doctors should sign the 
legal documents which include medical practitioner who is in charge of 
the hospital, a medical practitioner and neurologist nominated by the 
hospital and the doctor who is treating the patient.  
Maastricht Categories for Non-Heart –Beating Donors  
      Category I : dead on arrival 
      Category II : unsuccessful resuscitation 
      Category III : awaiting cardiac death 
      Category IV : cardiac death in a brain-dead donor 
            Category I and II DCD donors are also referred to as uncontrolled 
donors, are asystolic and pulseless after adequate but failed attempts at 
resuscitation. Uncontrolled DCD is the most common form in Spain and 
Japan. Category III or controlled donors is the most common form in 
United States. Category IV donors are referred as crashing donors, who 
become hemodynamically unstable enroute to organ retrieval after a 
diagnosis of brain death. 
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             Donation after cardiac death is associated with high rate of 
delayed graft function, but long-term graft survival is similar when 
compared to that of brain-dead donors.  
DECEASED DONOR MAINTENANCE IN ICU 
  Deceased donors are maintained by a team of dedicated 
Anaesthetists who perform the apnoea test twice in a six hour interval. 
The same is confirmed by Neurologist.  To ensure adequate tissue 
perfusion for oxygenation by maintaining the mean arterial pressure of 
the organs is the overall goal. The most common problems encountered 
during cadaver maintenance are hypotension, hypoxia, pulmonary 
oedema, cardiac arrest and renal shut down. 
            The following tests are done after the first apnoea test is 
performed: 
x Blood grouping and typing 
x Hepatitis B surface antigen 
x Human immunodeficiency virus I & II 
x  Hepatitis C virus 
x  Renal function tests 
x Liver function tests 
x Complete hemogram including coagulation profile 
20 
 
 
 
ROLE OF TRANSPLANT COORDINATOR 
Once it is confirmed that there are no contraindications for 
donation the transplant coordinator is required to: 
x Counsel the family for organ donation and seek their consent 
x Inform all other transplant team personnel 
x Complete all legal formalities except for filling the Brain Death 
form (Form 8) 
x Obtain drugs and fluids necessary for the donor 
 
ORGANS RETRIEVAL 
The removal of kidneys is part of multi-organ procurement and 
frequently includes harvesting of liver, heart and sometimes lungs and 
pancreas. Corneal retrieval can take place at the end of solid organs 
removal. The principles of organ removal include wide exposure and in 
situ perfusion with cold intracellular-based fluids to preserve the organs. 
The organs after cross-clamping are removed in the following order – 
heart, lungs, liver, pancreas and kidneys. 
The organs should be removed with utmost care to avoid any 
anatomic damage and to preserve their vasculature. After all the efforts 
have been taken to identify, certify, obtain consent and ensure 
maintenance of a potential donor it would be very frustrating to lose an 
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organ due to technical errors.  The relatively high incidence of multiple 
vessels in kidneys necessitates careful dissection. It is best that the team 
that is going to perform transplant should also retrieve it.25 
PERFUSION FLUID 
 The Celsior-solution, UW (University of Wisconsin) and HTK 
(histidine-tryptophan-ketoglutarate) solution all are equally effective and 
are standard for multi-organ and single kidney harvesting procedure .26 
Perfusion with crystalloid solution  is sufficient for living donors, in 
whom a long cold ischemia time is not expected. 
Aims of modern kidney storage solutions 27 
• Reduce the cell-swelling during ischemia 
• Maintaining the intra- and extra-cellular electrolyte 
gradient   
• Acidosis buffering 
• Giving energy reserve 
• Decreasing reperfusion and oxidative injury 
The two methods of kidney preservation are: 
• Cold perfusion initially followed by ice storage. 
• Continuous machine-perfusion         
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(The latter is preferred for non heart-beating donors and 
marginal donors). 
Duration of organ preservation: 
The  cold ischemic time should be kept as minimum as possible.  
Elderly donors more than fifty-five years and marginal donors are much 
more sensitive to ischemia when compared to young donors. 
Hypothermic organ preservation lowers the metabolic rate, preserves 
stores of adenosine tri phosphate, and prevents formation of oxygen-free 
radicals during the reperfusion phase. 
 
PACKING OF KIDNEYS FOR STORAGE AND 
TRANSPORTATION 
The  packing  of  kidney  is  done  by  three  bag  technique,  it  is  
found to be safe and keeps the kidney sterile, especially if plastic bags are 
used for packing. 
Only cold preservation should be used in the inside bag with 
kidney fully immersed in it. It must be ensured there should be no leaks 
in the bag before making  an   air-tight closure of the bag. 
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RECIPIENT PREPARATION 
The three senior most patients in the waiting list of the concerned 
blood-group are called for and Complement Dependent Cytotoxicity 
Crossmatch is performed. The patient with the least percentage of 
negative cross-match ( < 20 %) is selected as the recipient. 
INDUCTION AGENTS 
 The Kidney Disease : Improving Global Outcomes (KDIGO) 
Guidelines recommends to use induction therapy with a biologic agent to 
be  used  as  part  of  the  initial  immunosuppressive  regimen  .  It  also  
recommends Interleukin 2- receptor antagonist (Basiliximab) as the first-
line induction therapy. In renal transplant recipients with high 
immunologic risk lymphocyte-depleting agent, rather than an Interleukin 
2-receptor antagonist is preferred. 
We have used Anti-Thymocyte Globulin- rabbit origin (r ATG), 
in a dose of 1-1.5mg/kg body weight single dose in the peri-operative 
period. In the absence of rATG, we have used Basiliximab. In 
Government Hospitals Induction agents are given free of cost and is only 
available to the patient recently. Cytomegalovirus prophylaxis is given 
for three months to all patients who had received lymphocyte depleting 
agents as induction therapy. 
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IMMUNOSUPPRESSIVE DRUGS 
KDIGO recommends starting of immunosuppressive 
medications  prior  to  or  at  the  time  of  kidney  transplantation.  We  start  
immunosuppressive drugs one day prior to transplant. We start 
C.Tacrolimus in a dosage of 0.1 mg/kg, T. Mycophenolate mofetil 500 
mg twice daily and T. Prednisolone in a dosage of 0.5 mg/kg and tapered 
to 10 mg per day at the end of four months. 
IMMUNE SURVEILLANCE 
When a tissue from a donor who is genetically different is 
transplanted, the recipient mounts an immune response which ultimately 
results in the destruction of the graft. Continuous immune monitoring and 
surveillance have significantly reduced the rates of acute rejection. 
However the same has not translated into improved graft survival and 
long-term graft loss continues to be a problem. 
Based on the time of occurrence of infections, rejection is 
traditionally classified as hyper acute, early acute, late acute or chronic. 
The Banff criteria of renal allograft rejection classifies it into T cell 
mediated (acute or chronic), or antibody mediated (acute or chronic) 
based on the pathological features. It has updated the C4d staining 
characteristics and the presence of Donor Specific Antibodies. 
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Graft failure could be due to various immune and non-immune 
factors and identification of risk-factors both before and after transplant 
also enhances the success rate. The three important factors that influence 
the risk stratification are clinical factors, HLA typing and alloantibody 
screening. Hence both before and after transplantation immune 
surveillance is very important.28 
IMMUNOLOGICAL RISK 
This  was  well  stratified  by  Gebel  et  al  into  three  broad  risk  
categories for a given combination of the donor and the recipient. This 
was adapted by the British society for histocompatibility and British 
Transplantation Society which are as follows, 
1. High immunological risk: This is characterized by high 
titre of circulating antibodies at the time of transplant, 
which directed against the donor HLA antigens. 
2. Intermediate risk: which is characterised by historically 
documented donor reactive sensitisation but not 
documented at the time of transplant? 
3. Low risk: is characterised by lack of sensitisation or 
sensitisation with non donor specific antibodies. 
Hence it is clear that HLA typing and matching of the 
donor and recipient and alloantibody testing for Donor 
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Specific Antibodies are critical for immunological risk 
stratification. 
FACTORS AFFECTING GRAFT SURVIVAL 
Though there is a significant reduction in acute rejection rates 
with the introduction of Tacrolimus, Mycophenolate mofetil and 
Interleukin-2 Receptor Antagonist induction, the results of long-term 
graft survival in renal transplantation have been mixed.   The data from 
Collaborative study done at Europe show substantial improvement in 
graft survival half-life.28 But another study from United States show only 
modest improvement with graft survival half-life increase from 6.7 years 
in 1990 to 8.7 years in 2006 for Deceased Donor Renal Transplantation.29 
RISK FACTORS FOR GRAFT FAILURE 
They could be classified as, 
Donor factors :  age > 60 years, Female gender, Vascular 
disease , prolonged cold ischemia times as in Donation after cardiac death 
and Deceased donation and delayed graft function. 
Recipient : obesity,  Hypertension, hyperlipidemia and Diabetes 
Mellitus , smoking and non-adherence to immunosuppressive drugs and 
mismatch in the size and female gender. 
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Immunologic factors : Poor HLA matching, prior sensitisation, 
inadequate immunosuppression. 
CAUSES FOR GRAFT FAILURE30 
The major causes for graft failure are  
Immunological : Rejection both cellular and antibody mediated, non-
adherence to immunosuppressant. 
Non-immunological : recurrent or denovo glomerular disease,  Graft 
pyelonephritis,  BK virus nephropathy, CNI toxicity,  obstruction , 
vascular causes. 
ANALYSIS OF PATIENT AND GRAFT SURVIVAL31 
The results of the transplant unit have to be followed closely for 
future improvement.  
Kaplan–Meier probability estimate of patient and graft survival is 
the most widely accepted descriptor of outcome. Survival estimates is 
calculated at periods of time after transplantation and should be expressed 
with their 95% confidence intervals.  
 Kaplan–Meier survival estimates are calculated in three ways.  
x ‘Patient survival’ is calculated from the date of transplantation to 
the date of death or the date of the last follow-up.  
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x Non-censored for death graft survival  is calculated from the date 
of transplantation to the date of irreversible graft failure - return to 
long-term dialysis or retransplantation or the date of the last 
follow-up during the period when the transplant was still 
functioning or up to the date of death. Here, death with graft 
function is treated as graft failure.  
 
x  DeathϢcensored graft survival is calculated from the date of 
transplantation to the date of irreversible graft failure - return to 
longϢterm dialysis (or retransplantation) or the date of last 
followϢup during the period when the transplant was still 
functioning. If the patient dies with a functioning graft, the 
followϢup period is censored up to the date of death. 30 
. 
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OBSERVATION AND  
RESULTS 
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x Total no of Deceased donor transplantations : 73 
 
  
 
     Gender Frequency Percent 
 Male 54 74.0 
  Female 19 26.0 
  Total 73 100.0 
 
 
 
 
54
19
Gender
Male
Female
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BLOOD GROUP WISE DISTRIBUTION 
     
     BLOOD GROUP Frequency Percent 
 A 12 16.4 
  B 25 34.2 
  AB 7 9.6 
  O 29 39.7 
  Total 73 100.0 
   
 
CAUSES OF BRAIN DEATH 
x ROAD TRAFFIC ACCIDENT : 56 
x FALL FROM HEIGHT : 13 
46
14
6
2 2
2
0
SOURCE OF GRAFT
RGGGH
SMC
APOLLO
CMC
SRMC
LIFELINE
KAMAKSHI
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x ANEURYSMAL BLEED : 2 
x SUB-ARACHNOID HEMORRAGE : 1 
x TRAUMATIC ASPHYXIA : 
 
 
NATIVE KIDNEY DISEASE: 
 
 
 
 
 
 
 
 
 
56
13
2
1 1
CAUSES OF BRAIN DEATH
RTA
FALL FROM HT
ANEURYSMAL BLEED
SAH
TRAUMATIC ASPHYXIA
NATIVE KIDNEY DISEASE Frequency Percent 
 ADPKD 2 2.7 
  ALPORTS 2 2.7 
  CGN 27 37.0 
  FSGS 3 4.1 
  IgAN 1 1.4 
  NK 37 50.7 
  SLE 1 1.4 
  Total 73 100.0 
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DESCRIPTIVE STATISTICS 
 
Variable  N Minimum Maximum Mean Std. Deviation 
Age (years) 
73 18 57 34.03 7.893 
Cr- 1wk (mg/dl) 
67 .80 13.10 2.5269 2.34150 
Cr-1Mon 
59 .80 5.60 1.3034 .71026 
Cr- 6Mon 
41 .80 1.70 1.1415 .20122 
on HD-months 
71 1 60 20.14 13.011 
Recent Cr (mg/dl) 
40 .7 2.7 1.453 .4261 
Tacro Level (ng/ml) 
64 2 18 6.74 4.056 
Age of donor (years) 
73 12 68 33.51 13.299 
CIT (hours) 
72 3 15 8.01 2.737 
No of days alive 
73 0 1891 733.14 593.439 
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x The mean duration of Haemodialysis prior to transplant was 20.14 
(± 13) months. 
x The overall mean age of the recipient was 34 (± 7.8) years. 
x The overall mean age of the donor was 33.51 (± 13.3) years. 
x HTK  (  Custodiol  )  was  the  organ  perfusion  solution  used  in  all  
patients. 
x  The mean cold ischemic time was 8.01 (± 2.73) hours. 
x Total recipients who had received induction immunosuppression 
were 13 patients. 
x Anti-Thymocyte Globulin, rabbit origin (rATG) was used in 6 
patients. 
x Interleukin-2 receptor antagonists (Basiliximab) were used in 7 
patients. 
x  Significant intra-operative events encountered in 10 patients such 
as  
- Bleeding : 2 
- Mottling : 1 
- Hypotension : 4 
- Impending graft rupture : 1 
- Accessory artery to External iliac artery : 2 
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INTRA OP 
 
 
 
 
 
 
 
x Significant post-operative complications were encountered 
in 30 patients. 
POST OPERATIVE EVENTS 
 
 
 
 
 
-  Sepsis : 7 
- Delayed graft function : 6 
- Graft nephrectomy : 4 
- Persistent drain (lymphocele) : 9 
- Pancreatitis : 3 
- Right lower limb ischemia : 1 
 INTRA OP EVENTS Frequency Percent 
  Absent 
63 86.3 
  Present 
10 13.7 
  Total 
73 100.0 
POST OPERATIVE Frequency Percent 
 Absent 
43 58.9 
  Present 
30 41.1 
  Total 
73 100.0 
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INFECTIONS DURING FOLLOW UP 
- Pneumonitis : 7 
- Sepsis : 10 
- Recurrent UTI and BK virus : 1 
- HCV Related DCLD : 1 
- Mycobacterial tuberculosis – 3 (Joint TB in 1, Pulmonary in 
2) 
x Accessory renal arteries were found in 22(30.1%) patients, triple 
in4 and double in 18.  
GRAFT BIOPSY   
 
 
 
GRAFT FUNCTION 
 
  Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Normal 45 61.6 61.6 61.6 
DGF 23 31.5 31.5 93.2 
SGF 5 6.8 6.8 100.0 
Total 73 100.0 100.0   
 
 Frequency Percent Valid Percent 
Cumulative 
Percent 
Valid Need for 
Biosy 14 19.2 19.2 19.2 
Normal 
59 80.8 80.8 100.0 
Total 
73 100.0 100.0   
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x Mean tacrolimus levels on fourth postoperative day were : 6.75 
(±4.05) ng/ml 
x Acute cellular rejections were encountered in 7 (9.58 %) patients. 
x Acute antibody mediated rejection was encountered in 2 (2.74%) 
patients. 
x Acute tubular necrosis (ATN) – biopsy proven – was observed in 6 
(8.21 %) patients. 
x Mean follow up period was 4 years. 
x Recent mean serum creatinine is 1.45 (±0.42) mg/dl. 
x New onset of Diabetes after renal transplant (NODAT) was 
observed in 10(13.69 %) patients. 
x Post transplant Erythrocytosis was observed in 8 (10.96 %) 
patients. 
 
 
 
 
GRAFT SIDE 
 
  Frequency Percent 
 Right 
43 58.9 
  Left 
30 41.1 
  Total 
73 100.0 
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SEROLOGY STATUS 
 
x One patient was HBsAg positive prior to transplant 
x One patient was HCV positive prior to transplant 
x  One patient who was HCV negative prior to transplant 
turned out to be HCV positive post transplant. 
 
GENDER OF DONOR 
 
  Frequency Percent 
Valid Male 
57 78.1 
  Female 
16 21.9 
  Total 
73 100.0 
 
PATIENT SURVIVAL USING KAPLAN-MEIER 
 Number of Cases:  73        Censored:   28     ( 38.36%)   Events: 45 
 
    HCV Frequency Percent 
 Positive 
3 4.1 
  Negative 
70 95.9 
  Total 
73 100.0 
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 Survival Time Standard Error 95 % Confidence 
Interval 
Mean 1079 71 (939, 1219) 
Median 1168 144 (885, 1451) 
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x Patient survival at the end of 1 year is 89.33 % 
x Patient survival  at the end of 3 years is 50.40 % 
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GRAFT SURVIVAL (CENSORED FOR DEATH) 
Number of Cases:  73        Censored:   14     (19.18%)   Events: 59 
 Survival Time Standard Error 95 % Confidence 
Interval 
Mean 869 73 (725,1013) 
Median 752 206 (348,1156) 
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PATIENT STATUS 
 
  Frequency Percent 
Valid Dead 
28 38.4 
  Survive 
45 61.6 
  Total 
73 100.0 
 
 
¾ OUT OF 73 PATIENTS 28(38.4 %) DIED. 
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DISCUSSION  
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  Total number of deceased donor transplantations was 73 up to March 
2014. 
         Though the deceased donor programme began in the year, it started 
gathering momentum only after 2008, when a doctor couple donated their 
son’s organs who sustained RTA which drew widespread public 
attention. 
         In Tamil Nadu the total number of deceased donor transplantations 
was 425, and the total number of organs shared was 2315 including 825 
kidneys. 
GENDER DIFFERENCE 
             The number of male recipients was 74 % (n=54) outnumbering 
female recipients which the usual scenario even in live renal 
transplantation. The number of female recipients was only 26 % (n=19). 
SOURCE OF THE ALLOGRAFT 
             Rajiv Gandhi Government General Hospital (RGGGH) tops the 
list by contributing to 46 deceased donations out of 73 deceased donor 
transplantations in our hospital, which is a staggering 63 %. Being the 
biggest government hospital in the state, it is the top most referral 
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institute and sought after hospital in Chennai. In this hospital brain death 
certification is made mandatory. 
    Our institution tops the list next by contributing to 14 donors which 
comes to 19.1 %. The other private hospital from the city and the state 
contributed to the rest of organs donations. 
BLOOD GROUP WISE DISTRIBUTION 
      As is the prevalence of blood group so is the transplantation. O blood 
group being more common tops the list of transplantations, it accounts for 
39.7 % (n=29). B blood group tops the list next with 34.2 % (n=25) and 
A has 16.4 % (n=12) and AB blood group is the least prevalent blood 
group accounting for only 9.6 % (n=7) of the total deceased donor 
transplantation. 
CAUSES OF BRAIN DEATH 
          Road Traffic Accidents (RTA) tops the list accounting for the 
majority of donations. As is already evident from the gender of the 
donors the majority are males who sustain RTA without wearing an 
helmet. The next most common cause of death is fall from height, who 
are usually construction site labourers without adequate safety 
precautions. The other causes of brain death are  berry aneurysmal bleed, 
Sub-arachnoid hemorrage among hypertensives and alcoholics and 
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traumatic asphyxia in a factory worker due to fall of heavy object over his 
chest. 
 
 
NATIVE KIDNEY DISEASE 
          The prevalence of Native kidney disease among recipients is as 
follows, the cause is not known in the majority of patients, which is the 
usual scenario as they are asymptomatic in the earlier stages of the 
disease; they are on poor follow up after detection of renal failure and 
refusal for renal biopsy in the earlier stages of the disease. They usually 
present with overt uremic symptoms when they have small contracted 
kidneys and renal biopsy could not be performed. Hence the cause is 
presumed to be CGN/CIN in 37 (50.7 %) patients. 
1. Biopsy proven Chronic Glomerular Disease was demonstrated in 
only 27 (37 %) patients.   
2. Alport’s syndrome was the cause of renal failure in 2 (2.7 %) 
patients.  
3. Autosomal  Dominant  Polycystic  kidney  disease  (ADPKD)  was  
the cause of renal failure in 2 (2.7 %) patients, 
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4.  Focal Segmental Glomerulo sclerosis was the cause in another 
3(4.1 %) patients and  
5. Systemic Lupus Erythematosus was found in 1 patient (1.4 %). 
WAITING PERIOD PRIOR TO TRANSPLANT 
The mean duration of Haemodialysis prior to transplant was 20.14 
(±13) months. The median waiting period for transplantation is 1.5 years 
in our centre. The number of patients on each blood group is 15 except 
for AB blood group and the number deceased donor transplants per year 
are 10 on an average. Hence there is a long waiting period prior to 
transplant. 
MEAN AGE OF THE DONOR AND RECIPIENT 
The overall  mean of the donor and recipient  was 34 (± 7.8)  years 
and 33.51 (± 13.3) years, since most of the donors were male who sustain 
RTA, they are relatively young. The recipients also have to come for 
follow up every month and have withstand dialysis for at least two years, 
the average waiting period. Hence the recipients are also young. 
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ORGAN PERFUSION AND PRESERVATION 
          HTK ( Histidine-Trptophan-Alpha Ketoglutarate) – CUSTODIOL 
was used in all the deceased donor transplantations. The sterile three bag 
technique is used for packing and transportation is done in sterile ice. 
COLD-ISCHEMIC TIMES 
           The mean Cold Ischemic times was 8.01 (± 2.73) hours. It varied 
between a minimum of 3 hours when the organ harvest takes place in our 
centre and is up to 15 hours when the organ harvest takes place in other 
centres. 
     Delayed graft function (DGF) and Slow graft function (SGF) was 
observed whenever the cold ischemic time is more than 10 hours. Out of 
the 28 patients who had DGF and SGF, nearly twenty of them had cold 
ischemic time of more than 8 hours. 
INDUCTION AGENTS 
           Only induction agents are available very recently and it is being 
given totally free of cost in government hospitals. Only 13 patients had 
received induction agents out of 73 deceased donor transplantations. 
      Anti-Thymocyte Globulin – rabbit origin (rATG) was used in 6(8.21 
%) patients. A single dose of 1.5 mg/kg was given as intravenous infusion 
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in the preoperative and intraoperative period. T. Valganciclovir 450 mg 
twice daily is given for three months for CytomegaloVirus prophylaxis 
for all patients who had received ATG as induction agent. 
     Among the rATG group, 3 patients died, pneumonitis was the cause of 
death in all the three patients. One patient had knee joint tuberculosis and 
tuberculous laryngitis. 
      Interleukin-2 receptor blockers (Basiliximab) was used in 7(9.58 %) 
patients. Two doses of 20 mg each is given at 4 days interval. 
    Among the Basiliximab group one patient died due to pneumonitis of 
tubercular etiology. 
 
INTRAOPERATIVE EVENTS 
       The significant intra operative events that were encountered in 10 
patients are as follows, 
        Bleeding following clamp release necessitating two re -suturing of 
the graft artery anastamosis occurred in 2 patients, mottling of graft 
occurred in one patient, hypotension in 4 patients, impending graft 
rupture necessitating graft nephrectomy in one patient, accessory artery 
anstamosis to External Iliac Artery in two patients. 
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POST OPERATIVE EVENTS 
        The significant postoperative events encountered are as follows, 
- Sepsis in 7 patients 
- Delayed Graft Function in 6 patients 
- Graft Nephrectomy in 4 patients – 2 patients had impending 
graft rupture and 2 patients had graft artery thrombosis 
- Persistent drain due to lymphocele in 9 patients 
- Pancreatitis in 3 patients 
- Right lower limb ischemia following external iliac artery 
thrombosis in one patient 
 
INFECTIONS 
x       About 7 patients had Pneumonitis – mostly bacterial, one 
patient had Pneumocystits carinii pneumonitis 
x        Mycobacterial tuberculous infections were seen in 7 patients – 
4 patients had lymphnodal involvement, 2 patients had pulmonary 
tuberculosis, one had Knee joint & laryngeal involvement. 
x         One patient had recurrent Urinary Tract Infection and Graft 
dysfunction and was found to have BK Virus nephropathy. 
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x         Sepsis occurred in 10 patients, mostly within first 6 months of 
transplantation, when they are exposed to peak 
immunosuppression. 
x       Hepatitis C Virus related decompensated liver disease occurred 
in one patient. 
GRAFT BIOPSY 
Graft Biopsy was performed in 14 patients, 
x Acute cellular rejections were seen in 7 (9.58 %) patients. Out of 7,  
4 was early acute rejections and 3 was late acute rejections. All of 
them responded to steroids. 
x Acute Antibody Mediated rejections was seen in 2 (2.74 %) , both 
the improved with plamapheresis. 
x Acute Tubular Necrosis was seen in 6 (8.21 %) patients. 
FOLLOW-UP 
x THE MEAN FOLLOW UP PERIOD WAS 4 YEARS. 
x The recent mean serum creatinine is 1.45 mg/dl. 
x New onset of Diabetes after transplantation (NODAT) was seen in 
10 (13.69 %) patients. 
x Post transplant Erythrocytosis was observed in 8 (10.96 %) 
patients. 
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x The mean tacrolimus was 6.75 (±4.05) ng/ml as measured by 
Chemiluminiscent Microparticle Immunoassay. 
VIRAL SEROLOGY 
x One patient was HCV positive prior to transplant. 
x One patient was HBsAg positive prior to transplant , he died due to 
pneumonitis. 
x One patient who was HCV negative prior to transplant became 
HCV positive, had Decompensated liver disease and hepatic 
encephalopathy and died. 
PATIENT STATUS 
x Out of 73 renal transplantations 28(38.4 %) patients died. 
x Patient survival at the end of 1 year is 89.33 % and at the end of 4 
years is 56,40 %. (KAPLAN-MEIER ESTIMATES) 
GRAFT SURVIVAL (Censored for death) 
x Graft survival at the end of 1 year is 73 % and at the end of 3 years 
is 44%. 
The patient and graft survival rates are very much comparable to that 
of live related renal transplantation. 
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GSH – CADAVER Tx - SURVIVAL RATE –
comparison with other centers
n PATIENT  SURVIVAL GRAFT SURVIVAL
CENTER /  YEAR 1ST YR         2ND YR       3RD YR    4th YR 1ST YR 2ND YR 3RD YR         4th YR
MMC/GGH 108 83% 80% 77% 80% 76% 72%
STANLEY HOSP 73 89.33% 86.4% 82% 60%
APOLLO Chennai1 54 81.6 % - - 72.4% - -
SRMC,CHENNAI2 68 88.2% -- 61.7% 73.5% 67%
IKRDC,GUJRAT3 160 92.4% 87.9% 87.9% 79.5% 76.5% 74.8%
USRDS DATA4 13,780 92.6% 88.4% - 91.1% 86.4% -
1. J Assoc Physicians India. 2001 Apr;49:408-11
2.Transplant Proc. 2008 May;40(4):1104-7 
3. Indian J Nephrol. 2011 Jul;21(3):182-5. 
4. USRDS DATA 2012
  
 
    
  
     
 
 
 
 
53 
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
 
 
  
54 
 
 
 
CONCLUSIONS 
x The survival rates for both patient and graft of deceased 
donor transplantation is equal to that of live related renal 
transplantation. 
x Out of 73 deceased donor transplantations, 28 (38.4 %) 
patients died. 
x The causes of death were Sepsis and Delayed Graft Function 
- 20,Pneumonitis – 7, HCV related Decompensated liver 
disease -1. 
x Only way to combat the illicit organ trading (commercial 
renal transplantation ) is deceased donor transplantation. 
x Cadaver organs should be considered as nation’s resource 
and organs wasted should be treated as lives lost. 
x Our deceased donor program demonstrates that it can be 
implemented successfully as long as the framework of the 
program maintains transparency and adheres to established 
protocols. 
x Hence deceased donor transplantation is the need of the 
hour, which can be promoted by positive public attitude, 
identification of early brain death and certification, getting 
prompt consent for organ donation and adequate hospital 
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infrastructure are essential prerequisites for successful organ 
transplantation. 
x The state of TamilNadu would definitely be a good role 
model in this regard. 
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- I
/II
1 Kondiaraj 32 M O 5.10% 25.10.08 LIFELINE 1.7 1.6 1.4 CGN YES NO 36  - 1 NIL NIL 10 NEG - Radhakrishnan 49 M O+ NO NO LEFT 10 1 3 RA/CUFF RTA N 455 DIED(18/1/10) CAN HTK T/M/P I Cr.1 wk :
2 Balaraman 32 M B 5.10% 21.11.08 CBE 1.6 1.2 1.1 CGN YES NO 12  - 2 NIL NIL 8 NEG   - Gnanaprakasem 26 M B+ NO NO LEFT 8 2 NIL RTA N 425 DIED(20/1/10) NIL HTK T/M/P I Cr.1 mon : Creatinine value at 1 month Post Operation
3 Bala krishnan 31 M B 5.10% 14.1.09 APOLLO 8.7 1.4 1.3 CGN YES NO 6 1.8 3 NIL  NIL 10 NEG NODAT  Premkumar 48 M B+ NO NO LEFT 12 3 3RA RTA DGF 1891 ALIVE NIL HTK T/M/P I Cr.6 mon : Creatinine value at 6 months Post Operation
4 Lilly Theresa 29 M B 5.10% 28.1.09 APOLLO 2 1.3 1.2 CGN YES NO 6 1.6 4 Bleeding NIL 3 NEG NIL Jeevarathinam, 56 F B+ NO NO LEFT 12 4 NIL RTA N 1877 ALIVE NIL HTK T/M/P I Intra OP :
5 SasiKumar 29 M A 5.10% 4.2.09 STANLEY 1 1.2 -- CGN YES NO 28  - 5 NIL NIL 16.3 NEG      -  Suganya  15 F A+ NO NO LEFT 3 5 2RA RTA N 65 DIED(9/4/9) NIL HTK T/M/P I Post OP :
6 Baskar 38 M AB 5.10% 9.3.09 SRMC 2.3 1.6 1.7 CGN YES NO 3  - 6 NIL ACC.HT 10 NEG   -  Asha 20 F AB+ NO NO LEFT 10 6 NIL RTA N 96 DIED(15/6/9) HUS HTK T/M/P I Tacro level :
7 Dasan 48 M O 5.10% 14.3.09 CMC 4.2 4 1.6 ADPKD YES NO 24  - 7 NIL SEPSIS 2.9 HBV+   -  Jeyanthi Reddy 39 M O+ NO NO LEFT 10 7 NIL RTA DGF 45 DIED(30/4/9) NIL HTK T/M/P I CIT : Cold Ischemic Time
8 Sakthivel 27 M B 5.10% 26.4.09 APOLLO 13.1 -- -- CGN YES NO 30  - 8 Mottling Nephrectomy 3.1 HCV+   -  Chandru 27 M B+ NO NO LEFT 10 8 NIL RTA DGF 1747 ALIVE NIL HTK T/M/P I Tx - I/II :
9 Renuka 34 F B 5.10% 11.5.09 APOLO 1.4 1 0.9 IgAN YES NO 48 0.8 9 Venous leak NIL 14.2 NEG NIL  Dharani 19 F B+ NO NO LEFT 7 9 NIL RTA N 1734 ALIVE NIL HTK T/M/P I CGN :
10 Xavier 43 M O 5.10% 21.6.09 SRMC -- -- -- CGN YES NO 24   - 10 EIA Rt leg ischemia NEG    - Sivaprakasam 42 M O+ NO NO LEFT 12 10 2 RA RTA DGF 30 DIED(22/6/9) NIL HTK T/M/P I ADPKD :
11 GopiKrishnan 40 M B 5.10% 8.8.09 KAMAKSHI 3.1 1.2 1.3 FSGS YES NO 3 2.7 11 Hilum anas  Hypotension 18 NEG PTE John rayan 57 m B+ NO NO LEFT 10 11 NIL RTA DGF 1641 ALIVE NIL HTK T/M/P I IgAN :
12 Subramani 48 M O 5.10% 15.10.09 CMC 0.9 0.9 0.8 CGN YES NO 48   - 12 NIL NIL 8 NEG LATE ACR, PNEUMONITISVinoth Kumar 28 M O+ NO NO LEFT 11 12 NIL RTA N 1275 DIED(15/4/9) NIL HTK T/M/P I LVH :
13 JayaKumar 30 M B 5.10% 27.10.09 GH 2.1 1.2 1.1 CGN YES NO 1 1.3 13 NIL Pancreatitis 11 NEG PTE Iyyappan 28 M B+ NO NO RIGHT 10 13 NIL RTA N 1612 ALIVE NIL HTK T/M/P I RTA :
14 Eswaran 31 M B 5.10% 13.11.09 GH 7.3 5.6 -- CGN YES NO 12   - 14 Hypotension persistent DT 13 NEG     - Loganathan 23 M B+ NO NO RIGHT 12 14 2 RV Fall from ht DGF 213 DIED
(7/6/10)
ACR/
AHR
HTK T/M/P II T/M/P :
15 Prema 35 F A 5.10% 4.12.09 GH 7.4 1 1.2 CGN YES NO 24 1.3 15 Hypotension Ionotropes 3.8 NEG NIL JaiAnand 18 F A+ NO NO LEFT 12 15 2 RA Fall from ht DGF 1557 ALIVE NIL HTK T/M/P I PTE : Post transplant erythrocytosis
16 Revathy 24 F O 5.10% 12.12.09 GH 1.2 1.3 1.1 CGN YES NO 12 1.8 16 NIL SEPSIS/ARDS 15 NEG NIL Palanivel 24 M O+ NO NO RIGHT 11 16 NIL RTA N 1549 ALIVE NIL HTK T/M/P I NODATNew onset diabetes after transplant
17 Devaraj 46 M O 5.10% 16.12.09 GH 1.3 1.2 1.1 CGN YES NO 12   - 17 NIL NIL 10.3 NEG  - chandran 56 M O+ NO NO LEFT 11 17 NIL RTA N 1547 ALIVE NIL HTK T/M/P I
18 Palani 37 M O 5.10% 27.12.09 STANLEY 1.6 1.4 1.2 CGN YES NO 24   - 18 NIL NIL 15.2 NEG    - Jayabharthi 15 F O+ NO NO LEFT 3 18 NIL RTA N 1534 ALIVE NIL HTK T/M/P I
19 Elawarasan 22 M AB 5.10% 20.2.10 GH 1 0.9 -- CGN YES NO 24  - 19 NIL NIL 9 NEG NODAT, LATE ACR Vijay 12 M AB+ NO NO LEFT 5 19 NIL RTA N 1425 DIED(20/7/10) NIL HTK T/M/P I
20 Riyaz ali 25 M B 5.10% 27.2.10 GH 0.9 0.8 0.8 CGN YES NO 12 2 20 NIL NIL 12 NEG NODAT Venkatasen 29 M O+ NO NO RIGHT 5.5 20 2 RA RTA N 1474 ALIVE NIL HTK T/M/P I
21  Dass Prakash 31 M B 5.10% 19.3.10 GH 1.6 1.2 1 CGN YES NO 6 1.5 21 NIL NIL 10.9 NEG CAN, CNI TOXICITY Kuppan 45 M B+ NO NO RIGHT 10 21 NIL RTA N 1451 ALIVE NIL HTK T/M/P I
22 Rajan 36 M B 5.10% 6.4.10 GH 5.3 -- -- CGN YES NO 3   - 22 NIL Fungal sinusitis 7.9 NEG     - Malliga 34 F B+ NO NO RIGHT 8 22 NIL RTA DGF 10 DIED(16/4/10) NIL HTK T/M/P I
23 Devi   29 F O 5.10% 11.4.10 GH 1.2 0.9 0.9 CGN YES NO 1 1.8 23 NIL Stitch abscess 9.3 NEG FUNGAL SINUSITIS,UTILakshmi 45 F O+ NO NO RIGHT 9 23 NIL RTA N 1429 ALIVE NIL HTK T/M/P I
24 Nirmala 34 F AB 5.10% 14.4.10 STANLEY 6.5 0.9 0.8 CGN YES NO 36 1.3 24 NIL ATN 9.8 NEG NIL Rajadurai 19 M A+ NO NO LEFT 8 24 NIL Fall from ht DGF 1425 ALIVE NIL HTK T/M/P I
25 Meera Mohideen 35    M     O    5-10%  18.06.10 STANLEY 1.4 1.3 1.2 NK YES  NO 11 2 25 NIL NIL 4.9     NEG ACUTE MI Raghunathan 24   M    O+   NO     NO   LEFT 6 25        NIL        RTA N 240 DIED NIL HTK T/M/P I
26 Kumar 32 M    A    15-20%  24.06.10 GH 1.2 1.1 1 NK YES NO 13 1.8 26 NIL NIL 8.5 NEG CAN, CNI TOXICITY Prabhakar 22 M A+ NO NO RIGHT 8 26 2 RA Fall from ht N 1355 ALIVE NIL HTK T/M/P I
27 Kamaraj 43 M O 10-15% 01.07.10 STANLEY 1.2 1 1.1 NK YES NO 12    - 27 NIL NIL 5 NEG PNEUMONITIS Gaja 50 M O+ NO NO LEFT 5 27 NIL RTA DGF 270 DIED NIL HTK T/M/P I
28 Abdul Rahim 30 M AB 10-15% 04.07.10 GH 0.8 1.2 1 NK YES NO 9 1.6 28 NIL NIL 2.1 NEG NODAT,PNEUMONI Ravikumar 31 M AB+ NO NO RIGHT 7 28 NIL RTA N 1345 ALIVE NIL HTK T/M/P I
29 Nasir Ali 25 M O 10-15% 15.07.10 GH 2.5 1.1 1.2 NK YES NO 7 1.5 29 NIL N 3.9 NEG NODAT, ACR Ramesh 23 M O+ NO NO RIGHT 14.5 29 NIL RTA DGF 1334 ALIVE NIL HTK T/M/P I
30 Amthul valli 20 F B 10-15% 22.07.10 GH 1.2 1.1 1.2 NK YES NO 19 1.3 30 NIL NIL 4.2 NEG NIL Kasirajan 50 M B+ NO NO RIGHT 6.5 30 Acc ligated RTA N 1327 ALIVE NIL HTK T/M/P I
31 Periasamy 29 M A 5-10% 13.10.10 GH 2.2 1.2 1 NK YES NO 12 2.4 31 NIL NIL 5.9 NEG NIL Thadi Thenati 20 M A NO NO RIGHT 6 31 2 RA RTA DGF 1244 ALIVE NIL HTK T/M/P I
32 Arumugam 35 M A 10-15 % 19.10.10 STANLEY 1.2 1.1 1 NK YES NO 16     - 32 NIL NIL 6.8 NEG PNEUMONITIS Mohan 25 M A NO NO RIGHT 8 32 NIL RTA N 189 DIED NIL HTK T/M/P I
33 Narasingam 23 M B 10-15 % 30.10.10 GH 4.3 1.3 1.1 NK YES NO 4 1.3 33 NIL DGF/ PANCREATITIS NEG      - Desingh 32 M B NO NO LEFT 4 33 2 RA RTA DGF 1227 ALIVE NIL HTK T/M/P I
34 Ramadoss 57 M B 5-10 % 17.11.10 GH 1.2 1 1.1 ADPKD YES NO 14  - 34 NIL NIL 2.8 NEG      - Jyothi 60 F B NO NO RIGHT 8 34 NIL RTA DGF 180 DIED NIL HTK T/M/P I
35 Prakasam 41 M B 5-10% 06.12.10 STANLEY 1     -      - NK YES NO 32   - 35 NIL SEPSIS 5.1 NEG     - Annamalai 36 M B NO NO LEFT 8 35 2 RA RTA      - 1 DIED ATN HTK T/M/P I
36 Suja 27 F O 5-10% 28.12.10 GH 2.9 1.5 1.3 NK YES NO 8 2.1 36 NIL NIL 4.1 NEG LATE ACR Kali 23 F O+ NO NO RIGHT 8.5 36 2 RA RTA N 1168 ALIVE NIL HTK T/M/P I
37 Balaji 32 M O 10-15% 25.01.11 GH    -       -       - NK YES NO 16  - 37 NIL SEPSIS 6.2 NEG  NIL Jegan 20 M O+ NO NO RIGHT 5 37 NIL RTA N 15 DIIED NIL HTK T/M/P I
38 Poongodi 45 F B 10-15% 05.02.11 GH 1.1 1.1 0.9 NK YES NO 13   - 38 NIL NIL 3.7 HCV+ HCV DCLD Arun 22 M B NO NO LEFT 8 38 2 RA Fall from ht N 605 DIED NIL HTK T/M/P I
39 Sajeevan 32 M A 10-15% 09.03.11 STANLEY 1.3 1.1 1.4 NK YES NO 19 1.9 39 NIL NIL 6.6 NEG REC UTI, BK, CMV GRAFT Sivaprakasam 33 M A NO NO RIGHT 5 39  NIL RTA N 1096 ALIVE NIL HTK T/M/P I
40 Madhar 37 M O 5-10 % 27.03.11 GH    -       -       - NK YES NO 22   - 40 NIL SEPSIS 3.5 NEG      - Jagdish 27 M O+ NO NO RIGHT 8 40 2 RA Fall from ht N 7 DIED NIL HTK T/M/P I
41 Ramkumar 39 M A 10-15 % 29.03.11 GH      -    -    - NK YES NO 19    - 41 NIL SEPSIS/DIC 6.2 NEG      - Kumari 55 F A NO NO RIGHT 8 41 NIL Fall from ht DGF 5 DIED NIL HTK T/M/P I
42 Maheshwari 32 F O 10-15% 17.04.11 GH 1.4     -     - NK YES NO 15  - 42 NIL SEPSIS 7.4 NEG      - Pari 39 M O+ NO NO RIGHT 12 42 2 RA RTA N 7 DIED HTK T/M/P I
43 Perumal 26 M B 5-10% 27.04.11 GH 1.2 1.1 1 NK YES NO 6 1 43 NIL NIL 3.5 NEG PTE Rambabu 18 M B NO NO LEFT 6 43 3 RA/CUFF Fall from ht N 1048 ALIVE NIL HTK T/M/P I
44 Sathiamoorthy 40 M B 5% 26.06.11 GH 6.8   -     - NK YES NO 39     - 44 NIL DGF 3.9 NEG       - Ramya 15 F B NO NO RIGHT 7 44 NIL Aneurysmal bleedDGF/RVT 988 ALIVE NIL HTK T/M/P I
45 Alli 42 F O 5% 30.06.11 GH 1.1 1 1.1 NK YES NO 36 1.3 45 NIL NIL 5.8 NEG NIL Gurulingam 48 M O+ NO NO RIGHT 13 45 NIL RTA NIL 984 ALIVE NIL HTK T/M/P I
46 Murugan 40 M B 10% 02.07.11 GH 2.1 1.1 1.1 NK YES NO 12 1.2 46 NIL NIL 5 NEG PTE, REC UTI Manikandan 21 M B NO NO RIGHT 4 46 NIL RTA NIL 982 ALIVE NIL HTK T/M/P I
47 Arasu 24 M O 5% 09.07.11 GH 4.8 2     - NK YES NO 15   - 47 NIL DGF - 4 HD 4.8 NEG FUNGAL UTI, PNEUMONITISManikandan 27 M O+ NO NO LEFT 5 47 NIL RTA DGF 180 DIED ATN HTK T/M/P I
48 Samsath 35 F B 5-10% 08.09.11 GH 2 1.4   - NK YES NO 18   - 48 NIL DGF - 3 HD 2.1 NEG NIL Srinivasan 23 M B NO NO RIGHT 12 48 NIL RTA DGF 90 DIED (12/2011) ATN HTK T/M/P I
49 Mahalingam 35 M B 5-10% 01.09.11 GH 1 1.2 1 NK YES NO 22 1.2 49 NIL NIL 3.9 NEG PTE Arjunan 55 M B NO NO RIGHT 8 49 NIL RTA NIL 921 ALIVE NIL HTK T/M/P I
50 Kamatchi 31 F B 5-10 % 13.10.11 GH      -     -      - NK YES NO   - 50 IMPENDING GFAFT RUPTURE, NEPHRECTOMY DONE Suresh 36 M B NO NO RIGHT 12 50 NIL RTA     - 879 ALIVE HTK T/M/P I
51 Devarajesh 43 M O 10% 11.11.11 APOLLO 4.5    -      - NK YES NO 34   - 51 NIL SEPSIS/DIC NEG   - Lakshmi 68 F O+ YES NO RIGHT 12 51 NIL SAH DGF 7 DIED(19/11/2011) HTK T/M/P I
52 Kathirvel 35 M AB 10-15 % 17.02.12 GH 2.9 1.2 1.3 NK YES NO 22 1.6 52 NIL ACR NEG NIL Kathiresan 26 M AB+ YES NO RIGHT 6 52 NIL RTA SGF 754 ALIVE ACR HTK T/M/P I
53 Shanmugaperumal18 M A 5-10 % 19.02.12 GH 1.3 1.2 1.5 ALPORTSYES NO 32 1.5 53 NIL MET ACIDOSIS NEG NIL Marimuthu 28 M A NO NO RIGHT 53 NIL RTA DGF 752 ALIVE ATN HTK T/M/P I
54 Kandasamy 36 M B 5-10% 15.03.12 GH 1.5 1.6 1.2 NK YES NO 48 1.2 54 NIL ACR NEG NODAT, RT LUNG MUCOR Bhavani 36 F B NO NO RIGHT 6 54 NIL RTA 725 ALIVE NIL HTK T/M/P I
55 Sivamani 29 M O 5-10 % 23.03.12 GH 3.7 1.2 1.1 FSGS YES NO 12 1.3 55 NIL DGF - 7 HD NEG PTE Manikandan 22 M O+ NO NO RIGHT 6 55 2 RA/CUFF RTA DGF 717 ALIVE NIL HTK T/M/P I
56 Srinivasan 33 M AB 5-10 % 22.06.12 GH 1.1 1     - NK YES NO 3 1.4 56 NIL NIL 4.1 NEG NIL Suresh 25 M AB+ NO NO RIGHT 6 56 NIL Fall AT HOME N 627 ALIVE NIL HTK T/M/P I
57 Ranjithkumar 26 M O 5-10% 06.07.12 GH 1.8 1.1    - FSGS YES NO   - 57 NIL SEPSIS/ATN 6.1 NEG LEFT LUNG ABSCESS Suresh 26 M O+ NO NO RIGHT 6 57 NIL RTA 120 DIED 4 months,lung abscessATN HTK T/M/P I
66 Haripriya 23 F O 5-10 % 09.04.2013 GH 1.5 1.1 1.3 NK YES NO 48 1 66 NIL NIL 2.4 NEG NIL 42 M O+ NO NO LEFT 7.5 66 NIL RTA NIL 285 ALIVE NIL HTK T/M/P I
67 Priyamvadha 34 F O 5-10 % 25.04.13 STANLEY 1.2 1.1    - NK YES NO 36 1.1 67 NIL NIL 5.9 NEG NIL 40 M O+ NO NO RIGHT 4 67 NIL RTA NIL 301 ALIVE NIL HTK T/M/P I
68 Anandhan 38 M O 5-10 % 17.05.13 STANLEY 1.2 1.3 NK YES NO 28      - 68 NIL NIL 16.3 NEG NIL 44 M O+ NO NO RIGHT 6 68 NIL RTA NIL 275 DIED(1/14) NIL HTK T/M/P I
69 Mohammed Aasim23 M O 5-10 % 14.06.13 STANLEY 1.7 1.4 ALPORTSYES NO 24 1.7 69 NIL PNEUMONITIS 2.2 NEG PNEUMONITIS 41 M O+ NO NO LEFT 5 69 NIL FALL SGF 346 ALIVE ATN HTK T/M/P I
70 Shanmugaiah 32 M A 5-10 % 12.07.13 GH 1.4 1.1 NK YES NO 34      - 70 NIL NIL 8.7 NEG NIL 25 M A NO NO RIGHT 5.5 70 NIL RTA NIL 180 DIED NIL HTK T/M/P I
71 Gnanavel 30 M O 5-10 % 26.07.2013 STANLEY 1.5 1.4 NK YES NO 18 1.3 71 NIL NIL 6.6 NEG NIL 40 M O+ NO NO LEFT 10 712 RA ACC LIGATED RTA SGF 238 ALIVE ATN HTK T/M/P I
72 Priya 47 F     O 5-10 % 15.09.13 GH NK YES NO 24        - 72 GRAFT ART THROMBOSIS NEG GRAFT NEPHRECTOMY DONE 35 M O+ NO NO LEFT 5.5 72GRAFT NEPHRECTOMY 0 ALIVE DGF HTK T/M/P I
73 Rechel 40 F AB 5-10 % STANLEY 1      -     - NK YES NO 36 1 73 NIL NIL 5.3  NIL 38 M AB NO NO LEFT 4 73 NIL RTA NIL 25 ALIVE NIL HTK T/M/P I
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